SCHEMBL1744060

SCHEMBL1744060

O=C(O)c1ccc2sc(-c3ccccc3)nc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.77
KDM4E B2RXH2 7/20 0.77
NFKB1 P19838 5/20 0.77
NFKB2 Q00653 5/20 0.77
RELA Q04206 5/20 0.77
LMNA P02545 1/20 0.77
NPC1 O15118 8/20 0.64
RAB9A P51151 8/20 0.64
HPGD P15428 5/20 0.63
STAT1 P42224 1/20 0.63
PKM P14618 3/20 0.59
ALDH1A1 P00352 3/20 0.58
GAA P10253 3/20 0.58
POLB P06746 3/20 0.58
MAPT P10636 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
MITF O75030 1/20 0.58
RECQL P46063 1/20 0.58
GFER P55789 1/20 0.58
PAX8 Q06710 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708400 0.92 NPC1 (0.66) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL121572 0.87 KDM4E (1.00) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL11562017 0.86 KDM4E (0.61) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL8534417 0.86 MAPT (0.79) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL11567645 0.86 RAB9A (0.68) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL26962452 0.86 NPC1 (0.61) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL31025226 0.86 RAB9A (0.65) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL11561206 0.82 SMN1; SMN2 (0.66) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL505728 0.82 KDM4E (0.69) SMN1; SMN2KDM4ENFKB1NFKB2RELA
SCHEMBL11141442 0.82 NPC1 (0.57) SMN1; SMN2KDM4ENFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024153226-A1 PYRAZOLE-FUSED CYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京普祺医药科技股份有限公司 2024-07-25 WO disclosed
CN-109180590-A A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free 福建医科大学 2019-01-11 CN disclosed
US-8592467-B2 Benzothiazole cyclobutyl amine derivatives ABBVIE INC. (US) 2013-11-26 US disclosed
EP-2386556-B1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands ABBVIE INC (US) 2013-10-23 EP disclosed
EP-1926729-B1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LAB (US) 2011-12-21 EP disclosed
EP-2386556-A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands Abbott Laboratories (US) 2011-11-16 EP disclosed
US-20110254413-A1 CASING OF ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF ASUSTEK COMPUTER INC. (TW) 2011-10-20 US disclosed
US-20090326222-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-12-31 US disclosed
US-7576110-B2 Benzothiazole cyclobutyl amine derivatives ABBOTT LABORATORIES (US) 2009-08-18 US disclosed
CN-101312966-A Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands ABBOTT LAB (US) 2008-11-26 CN disclosed
EP-1926729-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2008-06-04 EP disclosed
WO-2007038074-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2007-04-05 WO disclosed
US-20070066588-A1 Benzothiazole cyclobutyl amine derivatives ABBVIE INC. 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326222-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES HRH2, HRH4, HRH1 SMN1; SMN2 3835/4885KDM4E 3229/4885NFKB1 2442/4885
US-20070066588-A1 Benzothiazole cyclobutyl amine derivatives HRH2, HRH4, HRH1 SMN1; SMN2 3835/4885KDM4E 3229/4885NFKB1 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.